Fink Densford | January 4, 2018
Miracor Medical Systems said today it closed a $30.2 million (EU €25 million) round of funding as part of Series D financing round with funds slated to support further development and commercialization of its PiCSO impulse system, and announced it is moving its headquarters from Austria to Belgium.
The company’s PiCSO therapy is designed to be used during stenting procedures for patients affected by acute myocardial infarcts to improve pressure in the coronary venous system to improve microcirculatory flow and improve perfusion in the infarcted area.
The round was led by Shenzhen, China-based Ming Capital and co-led by a strategic investor and joined by newly invested SFPI, SRIW and Meusinvest and existing investors Earlybird Venture Capital, Delta Partners, SHS Gesellschaft für Beteiligungsmanagement, Biomed Invest and Peppermint Venture Partners.